Classifications

• • D—TEXTILES; PAPER
  • D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
  • D04H—MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
  • D04H3/00—Non-woven fabrics formed wholly or mainly of yarns or like filamentary material of substantial length
  • D04H3/08—Non-woven fabrics formed wholly or mainly of yarns or like filamentary material of substantial length characterised by the method of strengthening or consolidating
  • D04H3/16—Non-woven fabrics formed wholly or mainly of yarns or like filamentary material of substantial length characterised by the method of strengthening or consolidating with bonds between thermoplastic filaments produced in association with filament formation, e.g. immediately following extrusion
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
  • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
  • A61F2/0063—Implantable repair or support meshes, e.g. hernia meshes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
  • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
  • A61F2/02—Prostheses implantable into the body
  • A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
  • A61F2/06—Blood vessels
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
  • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
  • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
  • A61L15/26—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
  • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
  • A61L15/42—Use of materials characterised by their function or physical properties
  • A61L15/44—Medicaments
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
  • A61L27/14—Macromolecular materials
  • A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
  • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
  • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
  • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
  • A61L27/3813—Epithelial cells, e.g. keratinocytes, urothelial cells
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
  • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
  • A61L2300/412—Tissue-regenerating or healing or proliferative agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
  • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
  • A61L2300/602—Type of release, e.g. controlled, sustained, slow
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L2400/00—Materials characterised by their function or physical properties
  • A61L2400/12—Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
  • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
  • Y10T442/00—Fabric [woven, knitted, or nonwoven textile or cloth, etc.]
  • Y10T442/60—Nonwoven fabric [i.e., nonwoven strand or fiber material]
  • Y10T442/608—Including strand or fiber material which is of specific structural definition
  • Y10T442/614—Strand or fiber material specified as having microdimensions [i.e., microfiber]
  • Y10T442/615—Strand or fiber material is blended with another chemically different microfiber in the same layer
  • Y10T442/616—Blend of synthetic polymeric and inorganic microfibers

Definitions

• the present invention is directed to poly(ester-amide) structures fabricated for biomedical application.
• Biodegradable poly(ester-amide)s are known for use for administration of drugs admixed with or chemically linked thereto applied as a drug eluting film or coating and for use in the manufacture of medical devices. See WO 02/18477A2; U.S. Pat. No. 6,503,538; and Katsarava, R., et al., Journal of Polymer Science, Part A, Polymer Chemistry 37, 391-407 (1999). They have not heretofore been fabricated into a form suitable for burn treatment, wound coverage, artificial skin, or scaffolds for tissue engineering.
• biodegradable poly(ester-amide)s can be enlarged from the uses previously proposed, by fabricating the biodegradable poly (ester-amides) into non-woven fabric of electrospun fibers.
• the poly(ester amide)s as claimed in U.S. Pat. No. 6,503,538 can be fabricated into useful non-woven fabrics by electrospinning.
• the invention is directed to a non-woven fabric consisting essentially of biodegradable electrospun poly(ester amide) for use for biomedical application, which is sterilizable and has an average fiber diameter ranging from 0.1 to 10 micrometer, e.g., 1.0 to 4.0 micrometer, a median pore size ranging from 0.1 to 100 micrometer, e.g., 2 to 100 micrometers, a surface area ranging from 100 to 300 m 2 /g, e.g., 150 to 300 m 2 /g, an average thickness ranging from 0.01 to 0.500 mm, e.g., 0.05 to 0.200 mm, a flexural rigidity ranging from 10 to 80 mg ⁇ cm, an average air permeability ranging from 10 to 100 ft 3 /min/ft 2 , an average water vapor transmission rate ranging from 200 to 500 g/m 2 /24 hr, a wettability contact angle ranging from 40 to
• biodegradable means capable of being broken down into innocuous products by various enzymes such as trypsins, lipases and lysosomes in the normal functioning of the human body and living organisms (e.g., bacteria) and/or water environment.
• biomedical application means application to clinical medicine.
• the poly(ester-amide) of the non-woven fabric is preferably one that can be solution electrospun into fibers.
• the poly(ester amide) of the non-woven fabric has a reduced viscosity ranging from 1.0 to 2.0 dL/g, e.g., 1.2 to 2.0 dL/g and is selected from the group consisting of one or more subunits A, and one or more subunits B, and combinations thereof, where the one or more subunits A have the structure
• R 1 is (C 2 -C 20 ) alkylene
• R 3 is hydrogen, (C 1 -C 20 ) alkyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl or (C 6 -C 10 ) aryl (C 1 -C 6 ) alkyl; and where the one or more subunits B have the structure
• R 2 is hydrogen or (C 6 -C 10 ) aryl (C 1 -C 6 ) alkyl and where R 5 is (C 2 -C 20 ) alkylene.
• the poly(ester-amide) of the non-woven fabric in one case has the structure (I) where R 1 is (CH 2 ) 8 , R 3 is
• R 4 is C 4 -C 8 alkylene.
• the poly(ester-amide) within the preferred case described above, determined to be most preferred of the poly(ester-amide)s tested, for a scaffold for tissue engineering, has the structure
• Calcein-AM is available from Molecular Probes (Eugene, Oreg.).
• the cells used as model cells to show attachment and proliferation were keratinocytes, particularly Normal Human Epidermal Keratinocyte cell line (NHEK cell line), Catalog No. CC-2501 from Cambrex Bio Science Walkersville, Inc. (Walkersville, Md.) or Biolife Solutions, Inc. (Oswego, N.Y.). These cells were chosen for testing because of easy availability and ease of manipulation. This testing is relevant to use for a scaffold for tissue engineering because tissue engineering involves seeding of cells into a scaffold for proliferation into tissues.
• burn treatment including adjunct therapy for burn treatment, wound coverage, partial thickness wound repair, healing acceleration, artificial skin, barrier to prevent tissue adhesions after surgery and administration of drugs or other agent physically or chemically associated therewith, for these purposes.
• non-woven fabrics herein are advantageous over films of the same poly(ester-amide) in providing a three dimensional porous network structure that a two dimensional film does not have.
• the non-woven fabrics herein are advantageous over films of the same poly(amide-ester) because they have a larger surface area for the cells to attach to and proliferate.
• the drug or other agent e.g., drug or other agent is matrixed into the non-woven fabric.
• Sterilizability is determined as follows: Samples of nonwoven fabrics are cut to the size of the bottoms of wells of a 96-well microplate (1 ⁇ 4 inch). The samples are attached around the bottom edges with 15% poly(ester-amide) in chloroform solution. A microplate with samples therein is placed into a Medi-Plus ethylene oxide bag, the bag is sealed and air plasma sterilization is carried out using a Harrick Plasma Cleaner model PDC-32G (Harrick Scientific, N.Y.) on high setting for five minutes.
• Harrick Plasma Cleaner model PDC-32G Harrick Scientific, N.Y.
• Fiber diameter and pore size are determined as follows based on scanning electronmicroscopy (SEM) pictures using Scion Image for Windows (www.scioncorp.com/pages/scionimagewindows.htm): Pore size of nonwoven and average fiber diameter are measured from the SEM images using the Scion program. Electrospun fibrous poly(ester-amide) mats are sputter coated with gold for thirty seconds using a BAL-TEC sputter coater (Manchester, N.H.) (Bal-Tech SCD050), and the sputter coated mats are observed using a Hitachi S4500 (Mountain View, Calif.) scanning electron microscope and an accelerating voltage of 10 kV.
• SEM scanning electronmicroscopy
• Surface area is determined as follows: Surface area is analyzed using a Brunauer, Emmett and Teller (BET) surface area analyzer from Porous Materials, Inc. (Ithaca, N.Y.). A poly(ester amide) sample is cut and weighed and is then placed in a BET tube. The test is run at ⁇ 195.76° C. with adsorbate nitrogen gas entering the system at 20 microns/minute under vacuum. One mat is used for providing all the samples for obtaining average surface area data.
• BET Brunauer, Emmett and Teller
• Thickness is determined according to ASTM D1777-96 as follows: Measurements are carried out using a Sherman W. Frazier Compressometer using a circular, 9.525 mm diameter presser foot. Ten measurements are made at a pressure of 0.023 MPa (3.4 pounds per square inch) to obtained an average value.
• Flexural rigidity is measured according to ASTM D1388 as follows: Standard commercially available spun bonded polypropylene (40 GMS, i.e., 40 gms per square meter) nonwoven samples are cut into 6 ⁇ 1 inch strips. Poly(ester amide) constructs are cut into 3 ⁇ 1 inch strips. The strips are mounted on a horizontal platform with one end sloping at a 45 degree angle. Each strip is slowly pushed off the platform in such a way that it overhangs. The fabric bends down and from the length and weight per square centimeter, the flexural rigidity G (stiffness) is calculated according to the following equation.
• W mg/cm 2 (the weight per unit area) and c is the bending length—the length of overhang in cm/2.
• c the bending length—the length of overhang in cm/2.
• the flexural rigidity of the spun bonded polypropylene is used as a control.
• the units are denoted with the terminology mg ⁇ cm. Five measurements are made to obtain an average value.
• Air permeability is measured according to ASTM D737-96 as follows: Circular samples with a minimum diameter of 3.5 inches are mounted on a Frazier precision instrument (Silver Spring, Md.). The rate of airflow through the fabric is measured under a differential pressure range of 0-1.0 inches of water. The data is expressed in ft 3 air/min/ft 3 . The air permeability of spun bonded 40 GSM polypropylene nonwoven material is used as a control. Five measurements are made to obtain an average value.
• Water vapor transmission rate is determined according to ASTM D6701-01 as follows: Samples are cut into 2.5 inch diameter circles and weighed to obtain sample density (gms/m 2 ) ⁇ 10 mL of distilled water is placed into the bottom of model 305 water vapor permeability cups. Then the samples are mounted onto the cups. Each assembled system including cup, fabric and water is weighed at 0, 0.5, 1, 3, 5, 12, 24 and 48 hours. The test is performed at 21° C. and 65% relative humidity. Three measurements are made to obtain an average value for water vapor transmission rate (water vapor permeability).
• the water vapor transmission rate is calculated according to the equation (G/t)A where G is the weight change in grams, t is the time during which G occurred, in hours, and A is the test area (cup's mouth area) in m 2 . The results are expressed in grams moisture/m 2 fabric/24 hours.
• the water vapor transmission rate of spunbonded polypropylene 40 GSM nonwoven, is used as a control.
• Wettability contact angle is determined as follows: Film of each poly(ester amide) is cast by pouring a layer of approximate thickness of 0.500 mm of 7% weight/weight, poly(ester-amide) in chloroform solution, onto a Teflon® plate. When a uniform thickness layer is obtained, the plate is covered by a watch glass to decrease evaporation rate. Each film layer is dried at room temperature for twenty-four hours. After the twenty-four hour drying time, each film is pulled from its Teflon® plate and cut into three 0.5 inch by 0.5 inch samples. The samples are mounted onto the contact angle analyzer (Hingham, Mass.) stage with double sided tape.
• Hingham, Mass. contact angle analyzer
• Each stage is inserted into the analyzer and a small amount of distilled water or methylene iodide (CH 2 I 2 ) is dropped onto the sample and brought into the viewing area.
• CH 2 I 2 methylene iodide
• Tensile properties are determined as follows: Tensile stress, tensile strain, Young's modulus and tensile toughness of poly(ester amide) and spunbonded 40 GSM polypropylene are measured. The samples are cut into 1 ⁇ 6 cm rectangular shapes and are mounted with vertical orientation in an Instron testing machine, model 1166. Tests are performed using a gauge length of 50 mm and a cross-head speed of 50 mm/minute. Average fabric thickness is used for calculating the tensile properties. The strength of a spunbonded polypropylene 50 GSM nonwoven material is used as a control. Five specimens are tested to obtain the average tensile properties.
• Biodegradability is determined by in vitro ⁇ -chymotrypsin catalyzed hydrolysis as described in Katsarava, R., et al., Journal of Polymer Science: Part A. Polymer Chemistry 37, 391-407 (1999).
• Each poly(ester amide) (PEA) polymer is dissolved with m-cresol to a 0.25 g/dL concentration. After the PEA polymers are dissolved, the solution is poured into a model C572 Glass Cannon capillary viscometer. The capillary viscometer is placed into a VWR Scientific Model 1120 Constant Temperature Circulator and the temperature held constant at 25 degrees Celsius. Suction is applied to the solution until it is past the top mark. Once the solution flows past the mark, timed collection is started. The timed collection is ended when the solution passes the second mark. The procedure is repeated 5 times for the pure solvent (m-cresol) and each polymer solution. The reduced viscosity is calculated using the following equations.
• ⁇ s solution time (seconds)
• ⁇ p m-Cresol time (seconds)
• the non-woven fabric of the first embodiment is made by a method comprising solution electrospinning of poly(ester-amide) and varying thickness of the non-woven fabric and/or solution concentration and/or collection distance and/or voltage and/or fiber diameter to vary pore size.
• the polymerizations to provide the poly(ester-amide)s can be carried out by an interfacial technique or by active polymerization.
• poly(ester-amide)s described above can be prepared by active polymerization as described in Katsarava, R., et al., Journal of Polymer Science: Part A: Polymer Chemistry 37, 391-407 (1999); U.S. Pat. No. 6,503,538; and in WO 02/18477A2.
• the technique is heterophasic, with two fast-acting reactants dissolved in a pair of immiscible liquids, one of which is usually water.
• the aqueous phase typically contains the Lewis base—a diol, diamine or dithiol—along with any added base or other additive.
• the organic phase consists of a Lewis acid, such as an acid chloride, dissolved in suitable organic solvent, such as toluene, octane or pentane. Reaction occurs near the interface.”
• poly(ester-amide)s made for testing herein are as follows:
• GJ1, GJ2, GJ4 and GJ5 were synthesized with the lysine unit being in the benzyl ester form.
• the benzyl ester of the lysine unit was more than 90% converted by hydrogenolysis to the free acid form for electrospin processing.
• GJ4 40% of the benzyl ester in the lysine unit was converted by hydrogenolysis to the free acid form for electrospin processing.
• GJ5 was left entirely with the lysine unit in the benzyl ester form for electrospin processing.
• GJ1, GJ2, GJ4 and GJ5 were made by active polymerization.
• the molecular weight can be determined from the reduced viscosities.
• Solution or melt electrospinning can be used.
• the drug or other agent can be incorporated into polymer solution prior to solution electrospinning.
• Droplets are formed at the needles end.
• the charge on the needle provides an electric charge in the droplets emitting therefrom to overcome the surface tension of a droplet to produce a jet of polymer giving rise to unstable flow toward the collecting plate manifested by a series of electrically induced bending instabilities/whipping motions and evaporation of solvent and production of elongated polymer fibers and deposit thereof on the wax paper of the collection plate as a non-woven fabric of the polymer.
• the solvent selected for dissolving a poly(ester-amide) for the solution electrospinning should provide dissolution within 24 hours at room temperature and solution viscosity and evaporation rate suitable to produce fiber by solution electrospinning.
• a solution viscosity of 1-20 poise, a surface tension for the solution of 33-35 dyne/sm and a solvent evaporation rate of at least 1.0 g/m 2 /h are aimed for.
• GJ1 was not able to be solution electrospun. It wouldn't form fibers and the solution would just create spray droplets. However, it may be able to be melt electrospun.
• GJ4 provided the best solution electrospinning results—a single thin filament pulled out of the droplet during electrospinning.
• the poly(ester-amide) non-woven fabrics obtained had average fiber diameter ranging from 2 to 4 micrometer, a median pore size of 50 micrometer, a surface area of 220 m 2 /g, an average thickness of 0.1 mm, a flexural rigidity ranging from 4 to 65 mg ⁇ cm, an average air permeability ranging from 25 to 90 ft 3 /min/ft 2 , an average water vapor transmission rate ranging from 280 to 430 g/m 2 /hr, a wettability contact angle ranging from 60 to 75 degrees, tensile stress property ranging from 0.035 to 0.095 kgf/mm 2 , tensile strain property ranging from 125 to 795%, Young's modulus ranging from 0.9 to 14.5 MPa and tensile toughness ranging from 0.90 to 2.10 MPa.
• Pore size can be varied by varying thickness of the non-woven fabric. The greater the thickness, the smaller the pore size.
• Increasing the solution concentration causes increase in fiber diameter.
• Fiber diameter is related to collection distance. For example, in experiments carried out on poly(ester amide) 8P4, electrospun at 15% concentration in solution, use of a collection distance of 15 cm created fiber diameter of 2 ⁇ m whereas use of a collection distance of 10 cm created a fiber diameter of 2.35 ⁇ m. At 20 cm, the fiber diameter becomes larger because the collection plate is beginning to be moved outside the electrical charge field resulting in lesser force to draw the fiber to its full extension. Thus the collection distance had an initial inverse effect on fiber diameter as the collection distance increased. Fiber diameter increases with voltage increase.
• NHEK cells Normal human epidermal keratinocytes
• the constructs were maintained in an incubator at 37° C. with 5% CO 2 .
• the medium was changed every three days.
• 8P4 was considered the model for nonwoven fabric production and the following results were obtained on nonwoven fabric from 8P4.
• absorbencies (RFU) denoting cell proliferation were 14,000, 18,000 and 31,000 at days 1, 3 and 7 as compared to absorbencies of 22,000, 26,000 and 44,000 for a well with only NHEK cells and no scaffold.
• the nonwoven fabric from 8P4 from electrospinning at feed rate of 0.02 mL/min, 11 kV and 10 cm collection distance had properties as follows: Average fiber diameter of 3 micrometers, median pore size of 50 micrometers, a surface area of 220m 2 /g, an average fabric thickness of 0.102 mm, a flexural rigidity of 19.5 mg ⁇ cm, an air permeability of 31.8 ft 3 /min/ft 2 , an average water vapor transmission rate of 427 g/m 2 /24 hr, a wettability content angle of 66.4 degrees, tensile stress of 0.073 kgf/mm 2 , tensile strain of 144.5%, Young's modulus of 14.31 MPa, and tensile toughness of 0.902 MPa.
• the nonwoven fabric herein can incorporate drug or other agent.
• nonwoven fabric incorporating agent for accelerating wound healing or for burn treatment or adjunct therapy for burn treatment e.g., gallium nitrate, for administration of nitroxyl radical (e.g., 2,2,6,6-tetramethylpiperidine-1-oxy radical), e.g., to reduce intimal hyperplasia in vascular grafts or to reduce tissue adhesion by retarding smooth muscle cell proliferation, or for administration of rapamycin (sirolimus) to prevent tissue adhesion after abdominal or other surgery, or for administration of therapeutic protein (as suggested by incorporation into the fabric of the model protein albumin).
• nitroxyl radical e.g., 2,2,6,6-tetramethylpiperidine-1-oxy radical
• rapamycin sirolimus
• the homogeneous mixed drug (gallium nitrate)/polymer solution was electrospun at 15 kV under a steady flow rate of 0.025 mL/min using a spinneret with an orifice of diameter 0.2 mm as the jet with the distances of approximately 15-cm from the collecting plate.
• the electrospun fibers were collected in the form of thin fabric on a metal sheet (10 cm ⁇ 15 cm) wrapped with wax paper. The fibrous fabric is peeled off the collecting wax paper.
• a calibration curve was prepared as follows: Solutions of known concentrations of gallium nitrate in chloroform (not completely dissolved) were extracted with 10-mL deionized water. The electrical resistance of the aqueous solutions from extraction was measured. A calibration curve was constructed based on conductivity (inverse of measured resistance) and known concentration of gallium nitrate.
• Drug release was established at 1, 2, 3, 4, 5, 8, 12, 18 and 28 days by extraction with water and measuring conductivity and generating gallium nitrate release profiles for 1.2 grams of gallium nitrate per gram (8P4), 1.0 gram of gallium nitrate per gram (8P4) and 0.2 gm of gallium nitrate per gram (8P4). In each case there was a burst of drug release within the first 5 days. The drug release profile suggests that release time is independent of the concentration of gallium nitrate incorporation in the fiber.
• gallium nitrate in promoting wound healing is demonstrated by Staiano-Coico, L., J. Surgical Res. 103, 134-140 (2002).

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Engineering & Computer Science (AREA)
• Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Biomedical Technology (AREA)
• Transplantation (AREA)
• Oral & Maxillofacial Surgery (AREA)
• Epidemiology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Dermatology (AREA)
• Heart & Thoracic Surgery (AREA)
• Cardiology (AREA)
• Cell Biology (AREA)
• Vascular Medicine (AREA)
• Hematology (AREA)
• Medicinal Chemistry (AREA)
• Materials Engineering (AREA)
• Gastroenterology & Hepatology (AREA)
• Textile Engineering (AREA)
• Pulmonology (AREA)
• Urology & Nephrology (AREA)
• Zoology (AREA)
• Botany (AREA)
• Materials For Medical Uses (AREA)
• Nonwoven Fabrics (AREA)
• Polyamides (AREA)
• Spinning Methods And Devices For Manufacturing Artificial Fibers (AREA)

Priority Applications (9)

Applications Claiming Priority (2)

Related Child Applications (1)

Publications (1)

Family

ID=38225075

Family Applications (1)

Country Status (8)

Cited By (23)

Families Citing this family (5)

Citations (3)

Family Cites Families (7)

• 2006
  • 2006-12-05 US US11/633,665 patent/US20070155273A1/en not_active Abandoned
  • 2006-12-08 WO PCT/US2006/046740 patent/WO2007078568A2/en active Application Filing
  • 2006-12-08 AT AT06844973T patent/ATE471977T1/de not_active IP Right Cessation
  • 2006-12-08 JP JP2008545662A patent/JP2009520118A/ja active Pending
  • 2006-12-08 DE DE200660015099 patent/DE602006015099D1/de active Active
  • 2006-12-08 CA CA 2632953 patent/CA2632953A1/en not_active Abandoned
  • 2006-12-08 EP EP20060844973 patent/EP1960513B1/de not_active Not-in-force
  • 2006-12-08 AU AU2006333369A patent/AU2006333369A1/en not_active Abandoned

Patent Citations (3)

Also Published As

Similar Documents

Legal Events